866-997-4948(US-Canada Toll Free)

Saphris Analysis and Estimates from 2009 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 25 Pages


GlobalDatas pharmaceuticals report, Saphris Analysis and Estimates from 2009 to 2020 provides Saphris sales estimates for US and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Saphris including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Saphris including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Saphris in each of the seven major markets.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Schizophrenia
2.2 Symptoms
2.3 Schizophrenia Market
2.4 Epidemiology
2.5 Etiology
2.5.1 Genetic Factors
2.5.2 Environmental Factors
2.5.3 Abnormal Brain Structure
2.6 GlobalData Report Guidance

3 Schizophrenia: Market Characterization
3.1 Schizophrenia Market
3.2 Schizophrenia Market Forecasts and CAGR
3.3 Drivers of Schizophrenia Therapeutics Market
3.3.1 Patent Expiry of Leading Marketed Drugs
3.3.2 Increasing Patient Pool
3.3.3 High Prescription Rates
3.3.4 Low Patient Compliance Rate
3.3.5 High Unmet Need

4 Classification of Schizophrenia
4.1 Age of Onset of Schizophrenia
4.1.1 Pediatric / Adolescent / Childhood Schizophrenia
4.1.2 Adult Schizophrenia
4.2 Associated Symptoms
4.2.1 Paranoid Schizophrenia
4.2.2 Disorganized Schizophrenia
4.2.3 Catatonic Schizophrenia
4.2.4 Residual Schizophrenia
4.2.5 Undifferentiated Disorder

5 Treatment for Schizophrenia
5.1 Crisis Resolution Teams (CRT)
5.2 Voluntary and Compulsory Detention
5.3 Antipsychotics
5.3.1 Typical Antipsychotics
5.3.2 Atypical Antipsychotics
5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

6 Saphris
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.4 Factors Affecting Sales of Saphris
6.4.1 Sublingual Administration
6.4.2 Saphris’s Potential in Treating Negative Symptoms
6.4.3 Late Entrant in a Highly Mature and Competitive Market
6.4.4 Competition from Invega
6.5 Drug Evaluation
6.5.1 Drug Risk Benefit Score
6.5.2 Intensity of Competition
6.6 Sales Forecasts
6.6.1 Target Patient Pool of Saphris
6.6.2 Dosing
6.6.3 Market Penetration
6.6.4 Annual Cost of Therapy
6.6.5 Sales Projections of Saphris

7 Schizophrenia Market: Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources

List of Table


Table 1: Phase III Clinical Trial Results of Saphris 13
Table 2: Drug Risk Benefit Score 15
Table 3: Competitors of Saphris 16
Table 4: Saphris, Annual Treatment Costs, 2011 17
Table 5: Saphris, Schizophrenia, Global, Sales Estimates ($m), 20092020 18
Table 6: Saphris, Schizophrenia, The US, Sales Estimates ($m), 20092020 19
Table 7: Saphris, Schizophrenia, Japan, Sales Forecasts ($m), 20142020 20

List of Chart


Figure 1: Risk of Developing Schizophrenia 5
Figure 2: Environmental Factors in the Development of Schizophrenia 6
Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 20102020 7
Figure 4: Classification of Schizophrenia based on the Age of Disease Onset 9
Figure 5: Drug Model Diagram of Saphris 16
Figure 6: Saphris, Schizophrenia, Global, Sales Estimates($m), 20092020 18
Figure 7: Saphris, Schizophrenia, The US, Sales Estimates($m), 20092020 19
Figure 8: Saphris, Schizophrenia, Japan, Sales Forecasts($m), 20142020 20
Figure 9: Saphris, Schizophrenia, Global, Sales Distribution in Major Countries (%), 2018 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *